tributyrin has been researched along with Adenocarcinoma, Basal Cell in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Clarke, KO; Feinman, R; Harrison, LE | 1 |
Maurer, HR; Schröder, CP | 1 |
2 other study(ies) available for tributyrin and Adenocarcinoma, Basal Cell
Article | Year |
---|---|
Tributyrin, an oral butyrate analogue, induces apoptosis through the activation of caspase-3.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Butyrates; Caspase 3; Caspases; CDC2-CDC28 Kinases; Cell Cycle Proteins; Colonic Neoplasms; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinases; DNA-Binding Proteins; E2F Transcription Factors; E2F4 Transcription Factor; Enzyme Activation; G1 Phase; Neoplasm Proteins; Nuclear Proteins; Phenotype; Phenylbutyrates; Phosphorylation; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Retinoblastoma Protein; Transcription Factors; Triglycerides; Tumor Cells, Cultured | 2001 |
Tributyrin-induced differentiation promotes apoptosis of LS 174T colon cancer cells in vitro.
Topics: Adenocarcinoma; Alkaline Phosphatase; Apoptosis; Caspase Inhibitors; Caspases; Cell Cycle; Cell Differentiation; Cell Division; Colonic Neoplasms; Enzyme Inhibitors; Humans; Triglycerides; Tumor Cells, Cultured | 2002 |